The latest price target for aTyr Pharma (NASDAQ:ATYR) was reported by Cantor Fitzgerald on January 6, 2025. The analyst firm set a price target for $0.00 expecting ATYR to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for aTyr Pharma (NASDAQ:ATYR) was provided by Cantor Fitzgerald, and aTyr Pharma initiated their overweight rating.

There is no last upgrade for aTyr Pharma

There is no last downgrade for aTyr Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on January 6, 2025 so you should expect the next rating to be made available sometime around January 6, 2026.

While ratings are subjective and will change, the latest aTyr Pharma (ATYR) rating was a initiated with a price target of $0.00 to $0.00. The current price aTyr Pharma (ATYR) is trading at is $3.60, which is out of the analyst’s predicted range.